These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22751607)

  • 1. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic arthritis: pharmacoeconomic considerations.
    Olivieri I; Mantovani LG; D'Angelo S; Padula A; de Portu S
    Curr Rheumatol Rep; 2009 Aug; 11(4):263-9. PubMed ID: 19691929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriatic arthritis with biological agents.
    Ceponis A; Kavanaugh A
    Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.
    Cortesi PA; Scalone L; D'Angiolella L; Belisari A; Fusco F; Olivieri I; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S126-31. PubMed ID: 23072771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic considerations in the treatment of psoriatic arthritis.
    Kavanaugh A
    Rheumatology (Oxford); 2006 Jul; 45(7):790-1. PubMed ID: 16705044
    [No Abstract]   [Full Text] [Related]  

  • 9. Adalimumab in psoriatic arthritis.
    Salvarani C; Pipitone N; Catanoso M; Chiarolanza I; Boiardi L; Caruso A; Pazzola G; Macchioni P; Di Lernia V; Albertini G
    J Rheumatol Suppl; 2012 Jul; 89():77-81. PubMed ID: 22751600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts in psoriatic arthritis: pathogenesis and management.
    de Vlam K; Gottlieb AB; Mease PJ
    Acta Derm Venereol; 2014 Nov; 94(6):627-34. PubMed ID: 24573106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriatic arthritis update.
    Mease P
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):25-31. PubMed ID: 17121486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant cases of psoriatic arthritis: how to manage them.
    Atzeni F; Sarzi-Puttini P; Vena GA
    J Rheumatol Suppl; 2009 Aug; 83():73-5. PubMed ID: 19661549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care.
    Ruderman EM
    Am J Manag Care; 2002 Apr; 8(6 Suppl):S171-80. PubMed ID: 11990862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can biologic therapies be withdrawn or tapered in psoriatic arthritis?
    Moverley AR; Coates LC; Helliwell PS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S51-3. PubMed ID: 24129138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial.
    O'Dwyer JL; Meads DM; Hulme CT; Mcparland L; Brown S; Coates LC; Moverley AR; Emery P; Conaghan PG; Helliwell PS
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):462-468. PubMed ID: 28544822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?
    McInnes IB
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):9-11. PubMed ID: 27586796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis.
    Punzi L; Podswiadek M; Sfriso P; Oliviero F; Fiocco U; Todesco S
    Autoimmun Rev; 2007 Sep; 6(8):524-8. PubMed ID: 17854743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab in psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Kaloudi O; Cassarà E
    J Rheumatol Suppl; 2012 Jul; 89():71-3. PubMed ID: 22751598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriatic arthritis.
    Wollina U; Unger L; Heinig B; Kittner T
    Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.